ABBV vs. NBIX: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ABBV and NBIX, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ABBV dominates in value with a market cap of 321.13 billion USD, eclipsing NBIX’s 11.82 billion USD by roughly 27.16×.
ABBV’s beta of 0.55 points to much larger expected swings compared to NBIX’s calmer 0.26, suggesting both higher upside and downside potential.
| Symbol | ABBV | NBIX |
|---|---|---|
| Company Name | AbbVie Inc. | Neurocrine Biosciences, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - Specialty & Generic |
| CEO | Mr. Robert A. Michael CPA | Mr. Kyle W. Gano Ph.D. |
| Price | 181.8 USD | 119.46 USD |
| Market Cap | 321.13 billion USD | 11.82 billion USD |
| Beta | 0.55 | 0.26 |
| Exchange | NYSE | NASDAQ |
| IPO Date | January 2, 2013 | May 23, 1996 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ABBV and NBIX over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
For a detailed comparison of valuation metrics between ABBV and NBIX, please refer to the table below.
| Symbol | ABBV | NBIX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 76.62 | 38.95 |
| Forward PEG Ratio (TTM) | 7.16 | 1.34 |
| Price-to-Sales Ratio (P/S, TTM) | 5.60 | 4.90 |
| Price-to-Book Ratio (P/B, TTM) | 226.35 | 4.70 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 20.87 | 24.02 |
| EV-to-EBITDA (TTM) | 23.58 | 22.37 |
| EV-to-Sales (TTM) | 6.73 | 5.01 |
| EV-to-Free Cash Flow (TTM) | 25.08 | 24.53 |
Dividend Comparison
ABBV delivers a 3.51% dividend yield, blending income with growth, whereas NBIX appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.
| Symbol | ABBV | NBIX |
|---|---|---|
| Dividend Yield (TTM) | 3.51% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ABBV and NBIX, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ABBV’s current ratio of 0.76 signals a possible liquidity squeeze, while NBIX at 3.13 comfortably covers its short-term obligations.
- ABBV’s quick ratio of 0.64 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas NBIX at 3.02 maintains a comfortable buffer of liquid assets.
- ABBV is heavily leveraged (debt-to-equity ratio 49.22), which can boost returns but raises risk if borrowing costs climb, while NBIX at 0.18 keeps leverage at a more moderate level.
- ABBV (at 6.14) covers its interest payments, while NBIX shows “--” for minimal debt service.
| Symbol | ABBV | NBIX |
|---|---|---|
| Current Ratio (TTM) | 0.76 | 3.13 |
| Quick Ratio (TTM) | 0.64 | 3.02 |
| Debt-to-Equity Ratio (TTM) | 49.22 | 0.18 |
| Debt-to-Assets Ratio (TTM) | 0.51 | 0.12 |
| Interest Coverage Ratio (TTM) | 6.14 | -- |